Overview
Herpes zoster, commonly known as shingles, is a painful skin rash caused by the reactivation of the varicella‑zoster virus (VZV)—the same virus that causes chickenpox. After a person recovers from chickenpox, VZV lies dormant in nerve tissue. Years or decades later, the virus can reactivate, travel along a sensory nerve, and produce the characteristic band‑like rash.
Shingles can occur at any age, but it most often affects adults over 50. In the United States, roughly 1 in 3 people will develop shingles in their lifetime (CDC). Annually, there are about 1 million new cases in the U.S. alone, and the condition is responsible for an estimated 10,000–30,000 cases of post‑herpetic neuralgia (PHN), a debilitating chronic pain syndrome.
Symptoms
The classic presentation follows a predictable pattern, though not every patient experiences all features.
Typical cutaneous signs
- Prodrome (1‑5 days before rash): Tingling, burning, itching, or sharp pain localized to a single dermatome (area of skin supplied by one spinal nerve).
- Rash: Begins as erythematous (red) patches that quickly evolve into clusters of fluid‑filled vesicles.
- Vesicle progression: Vesicles mature over 2‑3 days, rupture, and crust over within 7‑10 days.
- Distribution: Usually unilateral and limited to one or two adjacent dermatomes. The most common sites are the thoracic region (chest/torso) and the cranio‑facial V1 distribution (forehead and eye).
Neurologic and systemic symptoms
- Sharp, stabbing or burning pain that may precede the rash.
- Fever, malaise, headache, and sometimes lymphadenopathy.
- Sensitivity to light (photophobia) if the ophthalmic branch of the trigeminal nerve is involved.
- Auditory symptoms (tinnitus, hearing loss) with Ramsay Hunt syndrome (facial nerve involvement).
Less common manifestations
- Disseminated zoster: widespread vesicles beyond a single dermatome, more common in immunocompromised patients.
- Zoster oticus (Ramsay Hunt): ear pain, vesicles in the ear canal, facial paralysis.
- Zoster meningitis/encephalitis: headache, neck stiffness, altered mental status (rare).
Causes and Risk Factors
Underlying cause
Shingles results from the reactivation of latent VZV. The virus remains in the dorsal root or cranial nerve ganglia after primary infection (chickenpox). When cell‑mediated immunity wanes, VZV replicates and travels along the sensory nerve to the skin.
Key risk factors
- Age ≥ 50 years – immune senescence reduces VZV‑specific T‑cell immunity.
- Immunosuppression – HIV infection, organ transplantation, chemotherapy, long‑term corticosteroids, biologic agents (e.g., anti‑TNF).
- Chronic medical conditions – diabetes, chronic lung disease, kidney disease.
- Physical or emotional stress – may blunt immune surveillance.
- History of chickenpox – virtually everyone who had varicella is at risk; those never infected (or never vaccinated) are not.
- Vaccination status – lack of prior shingles vaccination increases risk.
Diagnosis
In most cases, shingles is diagnosed clinically based on the characteristic dermatomal rash and pain. Laboratory testing is reserved for atypical presentations.
Clinical evaluation
- History of prodromal pain followed by unilateral vesicular eruption.
- Physical exam confirming dermatomal distribution and stage of lesions.
Laboratory & imaging tests (when needed)
- Polymerase chain reaction (PCR) of vesicular fluid – highly sensitive for detecting VZV DNA.
- Tzanck smear – shows multinucleated giant cells; not specific for VZV.
- Direct fluorescent antibody (DFA) testing – rapid identification of VZV in lesion specimens.
- Serology – usually unnecessary; VZV IgG is positive in most adults.
- Neuroimaging (MRI/CT) – indicated only if neurologic complications (e.g., meningitis, encephalitis, cranial nerve involvement) are suspected.
Treatment Options
Therapy aims to shorten the disease course, reduce pain, and prevent complications such as post‑herpetic neuralgia.
Antiviral medications
| Drug | Typical adult dose | Duration | Key notes |
|---|---|---|---|
| Acyclovir | 800 mg orally five times daily | 7‑10 days | Most affordable; requires frequent dosing. |
| Valacyclovir | 1 g orally three times daily | 7‑10 days | Better bioavailability; easier dosing. |
| Famciclovir | 500 mg orally three times daily | 7‑10 days | Alternative for patients with renal issues. |
Antivirals are most effective when started within 72 hours of rash onset. They reduce lesion healing time by ~1‑2 days and lower PHN risk by ~30 % (Mayo Clinic).
Pain management
- Topical agents: lidocaine 5 % patches, capsaicin cream.
- Oral analgesics: acetaminophen or NSAIDs for mild pain; opioid analgesics for severe acute pain (short‑term use only).
- Neuropathic pain drugs: gabapentin, pregabalin, or duloxetine—especially when pain persists beyond lesion crusting.
- Corticosteroids: oral prednisone may be added in select cases to reduce inflammation, but evidence of long‑term benefit is mixed; use under physician guidance.
Procedural interventions (for complications)
- Epidural or peripheral nerve blocks – provide targeted pain relief when oral meds are insufficient.
- Botulinum toxin injections – emerging option for refractory post‑herpetic neuralgia.
Supportive care
- Cool compresses to soothe itching.
- Keeping lesions clean and covered to prevent bacterial superinfection.
- Adequate hydration and rest.
Living with Zoster (Shingles)
While the acute phase resolves in 2‑4 weeks for most people, the pain can linger. Below are practical daily‑management tips.
Skin care
- Gently wash the rash with mild soap and water; pat dry.
- Apply a thin layer of petroleum jelly or an antiseptic ointment to keep vesicles moist and reduce crusting.
- Avoid scratching—use cool, wet compresses or antihistamines for itching.
Pain control
- Track pain intensity on a scale of 0‑10; adjust medications accordingly with your clinician’s input.
- Use a daily schedule for neuropathic agents (gabapentin, etc.) to maintain steady blood levels.
- Consider low‑impact activities (walking, stretching) to improve circulation without aggravating pain.
Lifestyle adjustments
- Prioritize sleep; maintain a dark, quiet bedroom.
- Limit caffeine and alcohol, which can worsen neuropathic pain.
- Stay hydrated and eat a balanced diet rich in vitamins A, C, E, and zinc to support skin healing.
- Practice stress‑reduction techniques (deep breathing, mindfulness, gentle yoga).
When to contact your healthcare provider
- Rash spreads beyond one dermatome or becomes widespread.
- Fever > 101 °F (38.3 °C) that persists > 48 hours.
- Severe eye pain, vision changes, or facial droop (possible ocular involvement).
- Pain that does not improve after 1 week of antiviral therapy.
Prevention
Vaccination
- Shingrix® (recombinant zoster vaccine) – two-dose series, > 90 % efficacy in adults ≥ 50 years and in immunocompromised populations. Recommended by CDC and WHO.
- Zostavax® (live attenuated) – older vaccine with ~70 % efficacy; now less favored due to lower effectiveness and contraindication in immunosuppressed patients.
Vaccination reduces the overall incidence of shingles by ~50‑70 % and the risk of PHN by > 70 % (CDC).
General measures
- Maintain a healthy immune system: regular exercise, balanced diet, adequate sleep.
- Manage chronic conditions (diabetes, HIV, etc.) under medical supervision.
- Avoid close contact with individuals who have active varicella infection if you are immunocompromised.
Complications
While most cases resolve without lasting effects, several serious complications can arise, especially in older or immunocompromised patients.
- Post‑herpetic neuralgia (PHN): Persistent pain > 90 days after rash resolution; occurs in 10‑20 % of patients ≥ 60 years.
- Ocular involvement (herpes zoster ophthalmicus): Keratitis, uveitis, vision loss; requires urgent ophthalmology evaluation.
- Neurologic sequelae: Ramsay Hunt syndrome (facial paralysis), meningitis, encephalitis, transverse myelitis.
- Bacterial superinfection: Impetigo or cellulitis of lesions; may need antibiotics.
- Disseminated zoster: Widespread vesicles, organ involvement (lungs, liver, brain); high mortality in immunocompromised hosts.
- Stroke: Increased risk within 6 months of ophthalmic zoster due to arterial inflammation.
When to Seek Emergency Care
- Severe, sudden onset eye pain, redness, blurred vision, or loss of vision (possible herpes zoster ophthalmicus).
- Facial droop, difficulty speaking or swallowing, or loss of taste (possible Ramsay Hunt syndrome or stroke).
- High fever (> 103 °F / 39.4 °C) with a rapidly spreading rash covering large areas of the body.
- Severe, unrelenting pain that is not controlled with prescribed medication and is accompanied by confusion, seizures, or weakness.
- Signs of bacterial infection: increasing redness, swelling, pus, or foul odor from lesions.
Prompt evaluation can prevent permanent vision loss, neurological damage, or life‑threatening infection.
Sources: CDC – Shingles (2023); Mayo Clinic – Shingles treatment (2024); NIH – National Institute of Neurological Disorders and Stroke; WHO – Varicella and herpes zoster vaccines (2022); Cleveland Clinic – Post‑herpetic neuralgia (2023); JAMA Dermatology – Efficacy of Shingrix vaccine (2021).